Amneal Pharmaceuticals recently received U.S. FDA approvals for its generic versions of RESTASIS® (cyclosporine ophthalmic emulsion 0.05%) and PROAIR® HFA (albuterol sulfate inhalation aerosol 90 mcg) ...

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator indicated to increase tear production in patients with dry eye syndrome. Cyclosporine ophthalmic emulsion 0.05% is a topical ...

DEAR DR. ROACH: My wife, who's 72, has had very dry eyes for a long time, so she uses Restasis (cyclosporine emulsion 0.05%) eye drops. Her co-pay (after meeting the deductible) last year was around ...

A dry dropper is a two-fly rig that combines a dry fly and either a nymph or emerger, allowing you to fish on the surface and subsurface at the same time. If you’re fishing shallow water but not ...

Who knew that memes could be deadly? Christopher Landon’s latest film, “Drop,” uses the absurd plot point of threatening memes to motivate its main character, Violet (Meghann Fahy), to comply with ...

Note: If you use other eye drops in addition to Restasis, you can probably still use those drops while you’re using Restasis. But make sure to check with your doctor about which eye drops are safe to ...

You may qualify for free Restasis through the drug’s manufacturer, myAbbVie Assist. That said, you won’t use your Medicare coverage. Restasis (cyclosporine), a brand-name eye drop for chronic dry eyes ...

Five years after “Freaky,” Christopher Landon is back with another Blumhouse fright fest. This time, everyone’s a suspect. In the official trailer for “Drop,” Meghann Fahy (“The White Lotus,” “The ...

Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Preeya K. Gupta, MD, discusses a clinical ...

Sight Sciences Inc (NASDAQ:SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease.